Effect of escitalopram dose and treatment duration on CSF Aβ levels in healthy older adults: A controlled clinical trial
| Autor: | Darsol Seok, Leslie M. Shaw, Anne M. Fagan, Joanne C. Beer, Raymond F. Suckow, John R. Cirrito, Jin-Moo Lee, Teresa Waligorska, Magdalena Korecka, B. Joy Snider, John C. Morris, Yvette I. Sheline, Irem Aselcioglu |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Male medicine.medical_specialty Treatment duration Citalopram Placebo Gastroenterology Article Cohort Studies 03 medical and health sciences 0302 clinical medicine Lumbar Internal medicine mental disorders medicine Escitalopram Humans Prospective Studies Prospective cohort study Aged Aged 80 and over Amyloid beta-Peptides Duration of Therapy Dose-Response Relationship Drug business.industry Middle Aged medicine.disease Healthy Volunteers Peptide Fragments Clinical trial 030104 developmental biology Female Neurology (clinical) Serotonin Alzheimer's disease business 030217 neurology & neurosurgery Selective Serotonin Reuptake Inhibitors medicine.drug |
| Zdroj: | Neurology |
| Popis: | ObjectiveTo determine whether treatment with escitalopram compared with placebo would lower CSF β-amyloid 42 (Aβ42) levels.RationaleSerotonin signaling suppresses Aβ42 in animal models of Alzheimer disease (AD) and young healthy humans. In a prospective study in older adults, we examined dose and treatment duration effects of escitalopram.MethodsUsing lumbar punctures to sample CSF levels before and after a course of escitalopram treatment, cognitively normal older adults (n = 114) were assigned to placebo, 20 mg escitalopram × 2 weeks, 20 mg escitalopram × 8 weeks, or 30 mg escitalopram × 8 weeks; CSF sampled pretreatment and posttreatment and within-subject percent change in Aβ42 was used as the primary outcome in subsequent analyses.ResultsAn overall 9.4% greater reduction in CSF Aβ42 was found in escitalopram-treated compared with placebo-treated groups (p < 0.001, 95% confidence interval [CI] 4.9%–14.2%, d = 0.81). Positive baseline Aβ status (CSF Aβ42 levels 42 reduction (p = 0.006, 95% CI −16.7% to 0.5%, d = −0.52) compared with negative baseline amyloid status (CSF Aβ42 levels >250 pg/mL).ConclusionsShort-term longitudinal doses of escitalopram decreased CSF Aβ42 in cognitively normal older adults, the target group for AD prevention.Clinicaltrials.gov identifierNCT02161458.Classification of evidenceThis study provides Class II evidence that for cognitively normal older adults, escitalopram decreases CSF Aβ42. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|